Actively Recruiting
Repurposing Low-Dose Clonidine for PTSD in Veterans
Led by Wake Forest University Health Sciences · Updated on 2026-03-31
32
Participants Needed
1
Research Sites
199 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Hypothesis: Veterans with PTSD prescribed clonidine will demonstrate improvements in PTSD symptoms, including daytime, nighttime, and sleep-related behaviors.
CONDITIONS
Official Title
Repurposing Low-Dose Clonidine for PTSD in Veterans
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- US military veteran
- Currently diagnosed with PTSD by a clinician or principal investigator
- Screening score of at least 40 on the PTSD Checklist-Military Version (PCL-5)
- Score of 10 or higher on PCL-5 intrusion items 1-5 or items 15-20
- Minimum scores on PCL-5 questions: one score of 2 on questions 1-5, one score of 2 on questions 6-7, two scores of 2 on questions 8-14, and two scores of 2 on questions 15-20
- Score of 3 or higher on Clinician-Administered PTSD Scale (CAPS) nightmare items B2 and E6
- Speaks and understands English
- Willing to attend clinic visits as scheduled
You will not qualify if you...
- Pregnant or breastfeeding
- Moderate or high risk of suicide based on recent Columbia-Suicide Severity Rating Scale (C-SSRS)
- Acute or unstable mental illness or cognitive issues interfering with study participation (e.g., active schizophrenia, uncontrolled bipolar disorder, neurocognitive impairment, moderate-severe traumatic brain injury)
- Currently receiving exposure therapy
- Enrolled in other behavioral health therapies within the last month
- Urgent hypertension (blood pressure above 160/100) or symptoms of hypertensive emergency
- Low blood pressure (below 100/60) or symptoms such as dizziness or palpitations
- Known contraindications to clonidine including hypersensitivity, certain heart conditions, pheochromocytoma, Raynaud's phenomenon, stage 5 kidney disease, recent heart attack or stroke
- Use of specific drugs in the past 30 days without prescription or not as prescribed (e.g., heroin, opiates, barbiturates, sedatives, cocaine, amphetamines, cannabis, hallucinogens, inhalants)
- Current diagnosis of opioid, cocaine, alcohol, or cannabis use disorder
- Diagnosis of sleep apnea with non-adherence to treatment
- Prescription of clonidine or related medications within the last 6 months
- Cognitive inability to participate as assessed by study team
- Has a legal guardian
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Aurora Psychiatric Hospital
Wauwatosa, Wisconsin, United States, 53213
Actively Recruiting
Research Team
K
Kevin Petranu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here